Traphagen Investment Advisors LLC Buys New Stake in Lucid Diagnostics Inc. $LUCD

Traphagen Investment Advisors LLC purchased a new stake in shares of Lucid Diagnostics Inc. (NASDAQ:LUCD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 29,295 shares of the company’s stock, valued at approximately $34,000.

A number of other hedge funds have also modified their holdings of the stock. Parallel Advisors LLC acquired a new position in shares of Lucid Diagnostics in the 2nd quarter worth $46,000. Goldman Sachs Group Inc. lifted its stake in Lucid Diagnostics by 35.7% in the first quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after acquiring an additional 22,727 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Lucid Diagnostics in the first quarter worth $2,813,000. Cubist Systematic Strategies LLC acquired a new position in shares of Lucid Diagnostics during the 1st quarter valued at about $39,000. Finally, Ghisallo Capital Management LLC acquired a new position in shares of Lucid Diagnostics during the 1st quarter valued at about $629,000. 74.01% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a research note on Wednesday, August 13th. Ascendiant Capital Markets lifted their price objective on Lucid Diagnostics from $7.75 to $8.00 and gave the company a “buy” rating in a report on Monday. BTIG Research boosted their target price on Lucid Diagnostics from $2.00 to $2.50 and gave the stock a “buy” rating in a report on Friday, September 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Saturday, September 27th. Finally, Wall Street Zen lowered shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lucid Diagnostics has an average rating of “Moderate Buy” and an average price target of $3.70.

Insider Buying and Selling at Lucid Diagnostics

In other Lucid Diagnostics news, Director Dennis Matheis purchased 100,000 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $1.02 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director owned 665,443 shares in the company, valued at approximately $678,751.86. This represents a 17.69% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 6.80% of the company’s stock.

Lucid Diagnostics Stock Performance

Shares of NASDAQ:LUCD opened at $1.05 on Wednesday. Lucid Diagnostics Inc. has a 52-week low of $0.75 and a 52-week high of $1.80. The company has a market capitalization of $140.15 million, a P/E ratio of -0.88 and a beta of 1.19. The company has a 50-day simple moving average of $1.08 and a 200 day simple moving average of $1.21.

About Lucid Diagnostics

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.